Evidence-based treatment of Parkinson's disease

Nicholas D. Child, Bryan Klassen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative disorders and is associated with neuronal loss in the dopaminergic neurons of the substantia nigra pars compacta, with resultant loss of striatal dopaminergic input. Levodopa therapy was the first treatment able to effect substantial improvement in motor symptoms and remains the most efficacious treatment for PD. This chapter analyzes how the first-line pharmacological treatments change the UPDRS motor score and affect the probability of motor fluctuations and dyskinesia in patients with early PD. It then examines to what extent do adjunctive pharmacologic therapies improve motor fluctuations or dyskinesia in patients with PD and levodopa-induced motor complications. The chapter also analyzes to what extent does deep brain stimulation targeting the subthalamic nucleus or globus pallidus interna improve motor fluctuations, dyskinesia, and quality of life in the patients. The trials discussed here include: the COMPARE trial, PD-SURG trial and the EARLYSTIM trial.

Original languageEnglish (US)
Title of host publicationEvidence-Based Neurology
Subtitle of host publicationManagement of Neurological Disorders: Second Edition
PublisherWiley-Blackwell
Pages191-208
Number of pages18
ISBN (Electronic)9781119067344
ISBN (Print)9780470657782
DOIs
StatePublished - Dec 11 2015

Fingerprint

Parkinson Disease
Dyskinesias
Levodopa
Therapeutics
Corpus Striatum
Subthalamic Nucleus
Globus Pallidus
Deep Brain Stimulation
Dopaminergic Neurons
Neurodegenerative Diseases
Quality of Life
Pharmacology

Keywords

  • Catechol-O-methyltransferase inhibitors
  • COMPARE trial
  • Deep brain stimulation
  • Dopamine agonists
  • EARLYSTIM trial
  • Levodopa-controlled release formulations
  • MAO-B inhibitors
  • Parkinson's disease
  • PD-SURG trial

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Child, N. D., & Klassen, B. (2015). Evidence-based treatment of Parkinson's disease. In Evidence-Based Neurology: Management of Neurological Disorders: Second Edition (pp. 191-208). Wiley-Blackwell. https://doi.org/10.1002/9781119067344.ch19

Evidence-based treatment of Parkinson's disease. / Child, Nicholas D.; Klassen, Bryan.

Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley-Blackwell, 2015. p. 191-208.

Research output: Chapter in Book/Report/Conference proceedingChapter

Child, ND & Klassen, B 2015, Evidence-based treatment of Parkinson's disease. in Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley-Blackwell, pp. 191-208. https://doi.org/10.1002/9781119067344.ch19
Child ND, Klassen B. Evidence-based treatment of Parkinson's disease. In Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley-Blackwell. 2015. p. 191-208 https://doi.org/10.1002/9781119067344.ch19
Child, Nicholas D. ; Klassen, Bryan. / Evidence-based treatment of Parkinson's disease. Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley-Blackwell, 2015. pp. 191-208
@inbook{1e4316e6f45c448c94b93a35761d11a4,
title = "Evidence-based treatment of Parkinson's disease",
abstract = "Parkinson's disease (PD) is one of the most common neurodegenerative disorders and is associated with neuronal loss in the dopaminergic neurons of the substantia nigra pars compacta, with resultant loss of striatal dopaminergic input. Levodopa therapy was the first treatment able to effect substantial improvement in motor symptoms and remains the most efficacious treatment for PD. This chapter analyzes how the first-line pharmacological treatments change the UPDRS motor score and affect the probability of motor fluctuations and dyskinesia in patients with early PD. It then examines to what extent do adjunctive pharmacologic therapies improve motor fluctuations or dyskinesia in patients with PD and levodopa-induced motor complications. The chapter also analyzes to what extent does deep brain stimulation targeting the subthalamic nucleus or globus pallidus interna improve motor fluctuations, dyskinesia, and quality of life in the patients. The trials discussed here include: the COMPARE trial, PD-SURG trial and the EARLYSTIM trial.",
keywords = "Catechol-O-methyltransferase inhibitors, COMPARE trial, Deep brain stimulation, Dopamine agonists, EARLYSTIM trial, Levodopa-controlled release formulations, MAO-B inhibitors, Parkinson's disease, PD-SURG trial",
author = "Child, {Nicholas D.} and Bryan Klassen",
year = "2015",
month = "12",
day = "11",
doi = "10.1002/9781119067344.ch19",
language = "English (US)",
isbn = "9780470657782",
pages = "191--208",
booktitle = "Evidence-Based Neurology",
publisher = "Wiley-Blackwell",
address = "United States",

}

TY - CHAP

T1 - Evidence-based treatment of Parkinson's disease

AU - Child, Nicholas D.

AU - Klassen, Bryan

PY - 2015/12/11

Y1 - 2015/12/11

N2 - Parkinson's disease (PD) is one of the most common neurodegenerative disorders and is associated with neuronal loss in the dopaminergic neurons of the substantia nigra pars compacta, with resultant loss of striatal dopaminergic input. Levodopa therapy was the first treatment able to effect substantial improvement in motor symptoms and remains the most efficacious treatment for PD. This chapter analyzes how the first-line pharmacological treatments change the UPDRS motor score and affect the probability of motor fluctuations and dyskinesia in patients with early PD. It then examines to what extent do adjunctive pharmacologic therapies improve motor fluctuations or dyskinesia in patients with PD and levodopa-induced motor complications. The chapter also analyzes to what extent does deep brain stimulation targeting the subthalamic nucleus or globus pallidus interna improve motor fluctuations, dyskinesia, and quality of life in the patients. The trials discussed here include: the COMPARE trial, PD-SURG trial and the EARLYSTIM trial.

AB - Parkinson's disease (PD) is one of the most common neurodegenerative disorders and is associated with neuronal loss in the dopaminergic neurons of the substantia nigra pars compacta, with resultant loss of striatal dopaminergic input. Levodopa therapy was the first treatment able to effect substantial improvement in motor symptoms and remains the most efficacious treatment for PD. This chapter analyzes how the first-line pharmacological treatments change the UPDRS motor score and affect the probability of motor fluctuations and dyskinesia in patients with early PD. It then examines to what extent do adjunctive pharmacologic therapies improve motor fluctuations or dyskinesia in patients with PD and levodopa-induced motor complications. The chapter also analyzes to what extent does deep brain stimulation targeting the subthalamic nucleus or globus pallidus interna improve motor fluctuations, dyskinesia, and quality of life in the patients. The trials discussed here include: the COMPARE trial, PD-SURG trial and the EARLYSTIM trial.

KW - Catechol-O-methyltransferase inhibitors

KW - COMPARE trial

KW - Deep brain stimulation

KW - Dopamine agonists

KW - EARLYSTIM trial

KW - Levodopa-controlled release formulations

KW - MAO-B inhibitors

KW - Parkinson's disease

KW - PD-SURG trial

UR - http://www.scopus.com/inward/record.url?scp=85017991370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017991370&partnerID=8YFLogxK

U2 - 10.1002/9781119067344.ch19

DO - 10.1002/9781119067344.ch19

M3 - Chapter

AN - SCOPUS:85017991370

SN - 9780470657782

SP - 191

EP - 208

BT - Evidence-Based Neurology

PB - Wiley-Blackwell

ER -